The short version of Research chemical fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-20. Anything still debated is marked as such rather than presented as settled.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic heptapeptide | Stabilized analog of tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form: TKPRPGP |
| Molecular formula | C33H57N11O9 | Monoisotopic mass about 751.9 Da |
| Appearance | White to off-white powder | Typically supplied as lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in common polar solvents |
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.
Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
== Clinical significance == A deficiency of this protein may be responsible for dermatosparaxis, a genetic defect of connective tissues. Some hereditary forms of lymphedema are caused by mutations in ADAMTS3.
When it is in an aqueous solution, neptunium can exist in any of its five possible oxidation states (+3 to +7) and each of these show a characteristic color. The stability of each oxidation state is strongly dependent on various factors, such as the presence of oxidizing or reducing agents, pH of the solution, presence of coordination complex-forming ligands, and even the concentration of neptunium in the solution.
== See also == κ-Opioid receptor § Antagonists List of investigational antidepressants List of investigational bipolar disorder drugs List of investigational substance-related disorder drugs Aticaprant and navacaprant
From the early days of the development of AI, there have been arguments put forward by ELIZA creator Joseph Weizenbaum and others about whether tasks that can be done by computers actually should be done by them, given the difference between computers and humans, and between quantitative calculations and qualitative, value-based judgements. In April 2023, it was reported that image generation AI has resulted in 70% of the jobs for video game illustrators in China being lost. In July 2023, developments in generative AI contributed to the 2023 Hollywood labor disputes. Fran Drescher, president of the Screen Actors Guild, declared that "artificial intelligence poses an existential threat to creative professions" during the 2023 SAG-AFTRA strike. Voice generation AI has been seen as a potential challenge to the voice acting sector. However, a 2025 study concluded that the US labor market had so far not experienced a discernible disruption from generative AI. Another study reported that Danish workers who used chatbots saved 2.8% of their time on average, and found no significant change in earnings or hours worked.
Sources: en.wikipedia.org
== Mathematics and logic == Contraction (operator theory), in operator theory, state of a bounded operator between normed vector spaces after suitable scaling Contraction hierarchies, in applied mathematics, a technique to speed up shortest-path routing Contraction mapping, a type of function on a metric space Edge contraction or vertex contraction, graph operations used in graph theory Tensor contraction, an operation on one or more tensors that arises from the natural pairing of a finite-dimensional vector space and its dual Interior product, a tensor contraction specifically of a differential form with a vector field Left contraction and right contraction of multivectors in a geometric algebra, extensions of the inner product One of the rules of conditional independence, in probability Contraction (logic), a structural rule in proof theory
Different 2A peptides have different peptide-bond-skipping efficiencies, with T2A and P2A being the most efficient and F2A the least efficient. Therefore, up to 50% of F2A-linked proteins can in fact be produced as a fusion protein, which might cause some unpredictable outcomes, including a gain of function. One study reported that 2A sites cause the ribosome to fall off approximately 60% of the time, and that, together with ribosome read-through of about 10% for P2A and T2A, this results in reducing expression of the downstream peptide chain by about 70%. However, the level of drop-off detected in this study varied widely depending on the exact construct used, with some constructs showing little evidence of drop-off; furthermore, within a tri-cistronic transcript it reported a higher level of ribosome drop-off after one 2A sequence than after two 2As combined, which is at odds with a linear model of translation. IRES Recombinant DNA
{\displaystyle {\ce {{^{238}_{92}U}+{}_{0}^{1}n->{}_{92}^{239}U->[\beta ^{-}][23.5\ {\ce {min}}]{}_{93}^{239}Np->[\beta ^{-}][2.3\ {\ce {days}}]{}_{94}^{239}Pu}}\left({\ce {->[\alpha ][2.4\cdot 10^{4}\ {\ce {years}}]}}\right){\ce {^{235}_{92}U}}}
== Veterinary uses == The data from two six-month field studies and an extended use field study demonstrated that bexagliflozin was over 80% effective in improving glycemic control in cats with diabetes mellitus. Bexagliflozin, sold under the brand name Bexacat, is an antidiabetic medication used to improve glycemic control in cats with diabetes. Bexacat is the first sodium-glucose cotransporter 2 (SGLT2) inhibitor new animal drug approved by the US Food and Drug Administration (FDA) in any animal species. It was approved for medical use in the United States in December 2022. Bexacat is sponsored by Increvet Inc., based in Boston, Massachusetts. Elanco licensed development and commercialization rights for bexagliflozin from Bexcafe, an affiliate of Increvet.
He commented on the blame for the war, "We might claim that Georgia initiated the war … but it appears at first impression more like a situation when somebody spits in your face twenty days on and finally you react by slapping that person back. Suddenly, the provocateur blames you for the overreaction and says, ‘I have only spit on you but I never hit you…." He further stated, "Russia was the first to breach the 1994 agreement that was negotiated. South Ossetia did not have right to keep heavy artillery on its territory under the terms of this agreement." In October 2008, Russian military expert Vladislav Shurygin wrote that Russia won the war because "the troops and headquarters were preparing for this war" since Spring 2008 when the General Staff began to plan an "operation to force Georgia to peace" and "these tasks were worked out in the spring and summer exercises of the North Caucasus Military District". He continued, "We won because at the staff offices of all levels, there were developed detailed plans in case of the outbreak of this war. [...] We won because in the chaos of muddle and confusion there were those who took responsibility. Who, in the absence of intelligible and clear instructions from Moscow, decided to begin to act according to the plans that were worked out." Shurygin concluded that "had we missed another 2-3 hours, Tskhinvali would have fallen, Georgians would cut off the Transcaucasian Highway".
Sources: en.wikipedia.org
Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.
It was developed in Russia, at the Institute of Molecular Genetics of the Russian Academy of Sciences, during the 1990s. Most published research originates from Russian institutions. Independent international replication remains limited.
Tuftsin is a natural tetrapeptide with the sequence Thr-Lys-Pro-Arg that participates in immune signaling. Selank extends that sequence with Pro-Gly-Pro at the C-terminus. The added residues are linked to greater resistance to enzymatic breakdown.
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.